People with type 1 diabetes mellitus (T1DM) face a distinct yet often overlooked danger: disordered eating behaviors that exploit their insulin dependence to control weight. This condition, known in medical circles as type 1 diabetes-related disordered eating (T1DE), merges the physical risks of diabetes with the psychological strain of eating disorders. People with T1DE have a three-fold mortality risk compared with those with T1DM who do not experience disordered eating.
T1DM is an autoimmune disorder where the pancreas stops insulin production entirely, forcing patients to track blood glucose levels through finger-prick tests or continuous monitors. Without insulin, glucose accumulates in the bloodstream, leading to life-threatening complications such as diabetic ketoacidosis (DKA). For individuals with T1DE, restricting insulin becomes a method of weight loss, creating a cycle of rapid weight shifts, metabolic instability, and emotional distress.
In the UK, approximately 400,000 individuals live with T1DM, with diagnoses frequently appearing in childhood. However, disordered eating within this group remains underrecognized. While the term “diabulimia” appears in media discussions, medical professionals prefer T1DE to encompass a broader range of behaviors, including insulin restriction, binge eating, or extreme dietary control. Research indicates that 30% of young people with T1DM restrict insulin to lose weight, though prevalence varies significantly across studies.
Deadly risks of insulin restriction
Eating disorders have one of the highest mortality and suicidality rates of any mental illness, and they are nearly twice as common in T1DM than in the general population. Insulin restriction results in increased levels of blood glucose and ketone levels, increasing the risk of DKA, which leads to more frequent hospital admissions and longer stays. It also makes a person more susceptible to accelerated long-term complications of diabetes, such as nephropathy, foot problems, and retinopathy. The physical consequences mirror starvation: dehydration, low blood pressure, weakened bones, and early reductions in bone mineral density.
Diagnosing T1DE presents significant challenges. Neither the ICD-11 nor the DSM-5 includes formal criteria for the condition, leaving clinicians to rely on proposed guidelines from the Royal College of Psychiatrists. These guidelines require three key elements: an intense fear of weight gain tied to insulin use, repeated insulin restriction (whether direct or indirect, such as severe carbohydrate avoidance), and behaviors that cause harm—physical, psychological, or functional.
Barriers to detection extend beyond diagnostic uncertainty. Patients often conceal their struggles due to shame or fear of judgment, while healthcare providers may overlook T1DE, attributing insulin restriction to diabetes-related exhaustion or hypoglycemia concerns. Warning signs include erratic blood glucose readings, frequent DKA episodes, or secrecy around diabetes management. Yet many with T1DE maintain a normal BMI (18.5–25), allowing clinicians to overlook concerns—particularly if HbA1c levels appear stable through indirect insulin restriction.
Pharmacists’ key role in early detection
Pharmacists, who frequently interact with T1DM patients, hold a key role in early detection. They often notice missed insulin prescriptions, unexplained weight changes, or extreme dietary patterns. Validated screening tools like the Diabetes Eating Problem Survey-Revised (DEPS-R) or the mSCOFF questionnaire (adapted for type 1 diabetes) can aid identification, though they must be used carefully. A high DEPS-R score alone does not confirm T1DE but can prompt further discussion.
The NHS has explored integrated care pathways linking diabetes and eating disorder services, with encouraging outcomes. A 12-month pilot at King’s College Hospital demonstrated reductions in HbA1c levels, fewer DKA admissions, and fewer severe hypoglycemic episodes. However, access remains inconsistent—most UK patients still manage separate diabetes and eating disorder services without the necessary cross-disciplinary oversight for safe care.
A 2024 parliamentary inquiry showed these gaps, advocating for funded specialist T1DE services, clearer diagnostic standards, and standardized treatment approaches. Early intervention improves results, yet pharmacists and doctors often lack the training to recognize T1DE or respond effectively. Addressing these knowledge gaps is essential to prevent worsening conditions.
How T1DE differs from other diabetes struggles
T1DE may be confused with needle aversion, hypoglycemia fear, diabetes burnout, or depression, but it is driven by intense weight and shape concerns. Patients can alter the amount of active insulin by exposing it to heat, which deliberately degrades the hormone. Injecting into areas of lipoatrophy reduces insulin absorption, providing another route to limit its effect. Incorrect placement of a pump cannula similarly diminishes delivery, completing a set of common manipulation techniques.
Pharmacists should watch for red flags such as a sudden HbA1c rise above 86 mmol/mol or highly erratic glucose patterns. When such indicators appear, they are advised to contact the diabetes team even if a definitive T1DE diagnosis remains uncertain. Screening questionnaires can aid discussion, yet they are difficult to embed in busy clinics and cannot replace full psychiatric assessment. Final interpretation must involve a consultant psychiatrist or an eating-disorder multidisciplinary team alongside the full psychosocial and physical health picture.